ruboxistaurin mesylate Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central MeSH PubChem

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1
  • InChIKey: ZCBUQCWBWNUWSU-SFHVURJKSA-N
  • Mol. Mass: 468.56
  • ALogP: 3.51
  • ChEMBL Molecule:
    ruboxistaurin  
More Chemistry

Pharmacology

Alternative names

13-((dimethylamino)methyl)-10,11,14,15-tetrahydro-4,9:16,21-dimetheno-1h,13h-dibenzo(e,k)pyrrolo(3,4-h)(1,4,13)oxadiazacyclohexadecene-1,3(2h)-dione | arxxant | ly333531 | ly 333531 | ly-333531 | ruboxistaurin | ruboxistaurin mesilate | ruboxistaurin mesilate hydrate | ruboxistaurin mesilate monohydrate | ruboxistaurin mesylate

Organizations (8)

Research & Development (8)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (8)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (8)


 

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 1 (Phase 3)

Diabetes Mellitus, Type 2 (Phase 3)

Diabetic Nephropathies (Phase 2)

Diabetic Neuropathies (Phase 3)

Diabetic Retinopathy (Phase 3)

Heart Failure (Phase 1/Phase 2)

Macular Edema (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial Organizations: 8

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue